Dr. Singal on the FDA Approval of Cabozantinib in HCC

In Partnership With:

Partner | Cancer Centers | <b>UT Southwestern Harold C. Simmons Comprehensive Cancer Center </b>

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).